Biochemistry, Genetics and Molecular Biology
AAA+
12%
ATPase
12%
BRCA1
74%
BRCA2
45%
Cancer Cell
100%
CDC25A
10%
Cell Activation
18%
Cell Cycle Checkpoint
12%
Cell Viability
12%
Centromere
12%
Chemokine
18%
Cisplatin
37%
Corepressor
18%
Cyclin E
37%
Cyclin E1
37%
DNA Binding
18%
DNA Condensation
12%
DNA Damage
94%
DNA Repair
29%
DNA Replication
24%
Downregulation
41%
Dynamics
74%
Epidermal Growth Factor Receptor
37%
Erlotinib
18%
Genetics
12%
Genome Instability
15%
Homologous Recombination
27%
Immune Response
18%
Immunocompetent Cell
18%
Mediator
37%
Messenger RNA
37%
Mitochondrial Membrane Transport Protein
12%
MUC1
37%
Natural Killer Cell
18%
Oncogene
63%
Oncogene C Myc
12%
Poly ADP Ribose Polymerase
23%
Protein Expression
18%
Proteomics
10%
Proto Oncogene
18%
Quantitative Proteomics
37%
RAD51
74%
Sister Chromatid
12%
Sister Chromatid Exchange
37%
STAT1
37%
STAT3
43%
Steady State
18%
Translocase
12%
Upregulation
31%
Wild Type
7%
Medicine and Dentistry
Ataxia Telangiectasia
16%
Binding Affinity
12%
Breast Cancer
5%
Breast Cancer Cell Line
17%
Cancer Cell
37%
Cell Cycle
9%
Cell Cycle Checkpoint
17%
Checkpoint Kinase 2
37%
Cisplatin
48%
Colorectal Carcinoma
5%
Differential Gene Expression
5%
Diffuse Large B-Cell Lymphoma
5%
Disease
5%
DNA Damage Response
25%
Double Stranded DNA
5%
Drug Delivery System
5%
Expression Analysis
5%
Gene Expression Profiling
5%
Immunohistochemistry
9%
Malignant Neoplasm
14%
Mediator
37%
Meningioma
37%
Neoplasm
38%
Non-Transformed Cell
5%
Oncogene
37%
Ovarian Cancer
42%
Ovarian Cancer Cell Line
10%
Radioactive Tracer
37%
Receptor Subtype
37%
RNA Sequence
5%
S Phase
5%
Somatostatin Receptor
37%
Surgery
8%
Tetraxetan
8%
The Cancer Genome Atlas
10%
Therapeutic Window
5%
Transformed Cell Line
5%
Treatment Response
5%
Triple Negative Breast Cancer
48%
Xenograft
8%
Keyphrases
800CW-TATE
29%
BRCA2
8%
Breast Cancer Susceptibility Gene 1 (BRCA1)
37%
DDX27
6%
DNA Lesions
37%
Dynamic Biomarkers
6%
EXO1
37%
FIGNL1
37%
G3BP2
9%
High-grade Serous Ovarian Cancer (HGSOC)
37%
MOCS3
6%
NAT10
12%
Octreotate
37%
Platinum-based Treatment
37%
Single-strand Annealing
16%
STING Pathway
6%
SUM149
6%
Tumor
12%
Vulnerability
8%
